Lantheus(NASDAQ) LNTH

Lantheus Holdings, Inc. NASDAQ:LNTH helps doctors see inside the body. It makes special fluids used for medical imaging scans. These tools help identify cancer and heart problems early.

Tools for Precise Diagnosis

• Oncology: PYLARIFY imaging agent for finding prostate cancer using a protein called prostate-specific membrane antigen (PSMA); generated $240.4 million in revenue for the three months ended June 30, 2026.
• Cardiology: DEFINITY microbubble agent used to improve the clarity of ultrasound heart scans; generated $88.3 million in revenue for the three months ended June 30, 2026.
• Neurology: Neuraceq positron emission tomography (PET) imaging tool used for Alzheimer's disease evaluation; produced $39.6 million in revenue for the three months ended June 30, 2026.
• Strategic Partnerships: Provides biomarkers and contract development and manufacturing organization (CDMO) services to other healthcare firms; generated $19.9 million in revenue for the three months ended June 30, 2026.

Growing Through Strategic Moves

• Entered a merger agreement with Curium US Holdings LLC on August 3, 2026, for $102.50 per share in cash.
• Completed the sale of the nuclear medicine business (SPECT) to SHINE on January 1, 2026, for approximately $131.2 million.
• Acquired Lantheus Biosciences in July 2025 to add new diagnostic tools for patients with Alzheimer's disease.
• Purchased Evergreen Theragnostics in April 2025 to improve manufacturing capabilities and drug discovery efforts.
• Received Food and Drug Administration (FDA) approval for PYLARIFY TruVu, a new imaging agent formulation, on March 6, 2026.

A Fast-Moving Supply Chain

Lantheus operates a global network of manufacturing sites to deliver imaging agents that have very short lifespans. Its reach extends across North America and Europe through direct sales and third-party distribution partners.

Recent Financial Results

• Revenue reached $388.2 million for the three months ended June 30, 2026, up 2.7% year over year.
• Net income was $75.0 million for the three months ended June 30, 2026, down 4.7% year over year.
• Market capitalization for the company reached $7.2 billion in the second quarter of 2026, up 28.5% year over year.
• The price-to-earnings ratio was 24.1 for the quarter ended June 30, 2026, up 35.5% year over year.

The Lantheus Evolution

Lantheus has shifted its focus toward high-growth radiopharmaceuticals through strategic acquisitions and new product approvals. Its move to divest older businesses and join with a larger partner marks a new phase in the company history.